NovaQuest Capital Management logo
  • About
    • Biopharma
    • Animal Health
    • Private Equity
  • Investments
  • Meet Our Team
  • News and Insights
  • Contact Us
  • Login

News and Insights

Sign up for Updates Follow NovaQuest on LinkedIn

Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital

5.4.22

FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)

4.28.22

Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis

3.29.22

NovaQuest Capital Management Acquires TechAccel’s Interest In Covenant Animal Health Partners

11.30.21

Azurity Pharmaceuticals Completes Acquisition of Arbor Pharmaceuticals

9.20.21

Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals

8.24.21

Dermavant Announces $200 Million of Financing

6.7.21

Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

6.1.21

Argenta Enters $30 Million Product Financing Agreement with NovaQuest to Accelerate New Veterinary Product Development

5.20.21

Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest

5.3.21
Load More
NovaQuest Logo
4208 Six Forks Road, Suite 920 Raleigh, NC 27609 (919) 459-8620
  • Investments
  • Meet Our Team
  • About NovaQuest
  • LP Login
  • Strategies
    • Biopharma
    • Animal Health
    • Private Equity
  • News and Insights
    • Stay Up to Date
Contact Us

© 2022 NovaQuest Capital Management. All Rights Reserved.

PRODUCT FINANCE™ is a trademark of NovaQuest Capital Management.

Privacy Policy & Terms of Use

Web Design by NMC